St. Elisabethen-Krankenhaus gGmbH

The Breast Center is exploring new endocrine strategies for ER‑positive/HER2‑negative early breast cancer in pre‑menopausal women, comparing a novel selective estrogen receptor degrader with standard aromatase inhibition.

• Anti‑proliferative efficacy of novel agents
• Optimization of hormone therapy sequencing
• Management of pre‑menopausal endocrine response

Conducted at St. Elisabethen‑Krankenhaus gGmbH, the program aims to refine treatment choices for patients with early‑stage disease.

A prospective study measures progression‑free survival and overall survival at 12 months to assess the impact of emerging therapies for advanced HER2‑negative, hormone‑receptor positive breast cancer.

• Survival analysis in real‑world settings
• Evaluation of new systemic options
• Identification of predictive biomarkers

The investigators seek data that can guide oncologists across Europe in managing advanced disease.

Researchers analyze the spatial, temporal and molecular patterns of ribociclib activity to uncover resistance mechanisms in breast cancer.

• Molecular signatures of drug response
• Pathways driving therapeutic resistance
• Strategies for personalized treatment adaptation

Insights will support precision‑oncology initiatives at the Breast Center.